Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer

DISEASE CHARACTERISTICS:

Women with histologically documented metastatic carcinoma of the breast

Bilateral disease allowed
Concurrent intraductal or lobular carcinoma in situ allowed

Measurable or evaluable recurrent metastatic disease (stage IV) documented by radiograph, CT scan, nuclear medicine scan, or physical exam

Biopsy of recurrent site(s) recommended but not required
Nonmeasurable disease allowed if tumor or metastatic disease has been previously removed or successfully treated
0 to 3+ HER2 amplification, as determined by FISH

No clinical evidence of active brain metastases

Patients with treated brain metastases (i.e., those who have received definitive radiation, chemotherapy, and/or underwent surgery) and are stable are eligible

Hormone receptor status:

Estrogen or progesterone receptor positive or negative

PATIENT CHARACTERISTICS:

Menopausal status not specified
Karnofsky performance status 70-100% OR ECOG performance status 0-2
Life expectancy at least 3 months
Granulocyte count at least 1,500/mm^3
Platelet count at least 50,000/mm^3
Hemoglobin greater than 8 g/dL
Bilirubin less than 1.5 times normal
AST, ALT, and alkaline phosphatase < 5 times upper normal
Creatinine less than 1.8 mg/dL
Creatinine clearance at least 60 mL/min
BUN less than 1.5 times normal
No myocardial infarction (MI) within the past year
No history of MI (> 1 year ago) with current coronary symptoms requiring medication
No current history of angina/coronary symptoms requiring medication
No clinical evidence of congestive heart failure requiring medical management
No significant congestive heart failure
No other uncontrolled or significant cardiovascular disease
Ejection fraction at least 45% at rest by MUGA

Systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg

BP must be controlled to meet the standard by anti-hypertensive medications for at least 7 days prior to the first infusion
PFT-FEV_1 at least 50% predicted
DLCO2 at least 50% predicted
FVC at least 50% predicted
No other malignancy within the past 3 years
No other serious medical or psychiatric illness that would preclude study participation
HIV negative
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Prior chemotherapy regimens allowed, including prior treatment on protocol WSU-2006-130
Prior vaccine therapy on protocol WSU-2006-130 allowed
More than 4 weeks to leukapheresis since prior hormonal therapy
No radiation to the axial skeleton within 4 weeks of leukapheresis

No concurrent hormonal therapy for breast cancer

Hormones administered for non-disease-related condition (e.g. insulin for diabetes) allowed
Concurrent steroids for adrenal failure, septic shock, or pulmonary toxicity allowed